Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for lithium-induced nephrogenic diabetes insipidus pilot study
2011-005970-41Phase 2Active
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acetazolamide in Arginine Vasopressin Resistance (AVP-R), sponsored by Radboud University Medical Center. Primary endpoints: Urine volume and Maximal urinary osmolality after dDAVP administration. Started Feb 2012; status: active.
02
Drugs
acetazolamide
03
Conditions
Arginine Vasopressin Resistance (AVP-R)
Beyond the preview
Go deeper on 2011-005970-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005970-41.